DE69207603T2 - Zusammensetzung und verfahren zur behandlung von zystischer fibrose - Google Patents
Zusammensetzung und verfahren zur behandlung von zystischer fibroseInfo
- Publication number
- DE69207603T2 DE69207603T2 DE69207603T DE69207603T DE69207603T2 DE 69207603 T2 DE69207603 T2 DE 69207603T2 DE 69207603 T DE69207603 T DE 69207603T DE 69207603 T DE69207603 T DE 69207603T DE 69207603 T2 DE69207603 T2 DE 69207603T2
- Authority
- DE
- Germany
- Prior art keywords
- macromolecule
- fibrose
- composition
- treating cystic
- cystic fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74590091A | 1991-08-16 | 1991-08-16 | |
PCT/US1992/004225 WO1993003709A1 (en) | 1991-08-16 | 1992-05-19 | Composition and method for treating cystic fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69207603D1 DE69207603D1 (de) | 1996-02-22 |
DE69207603T2 true DE69207603T2 (de) | 1996-09-12 |
Family
ID=24998709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69207603T Expired - Fee Related DE69207603T2 (de) | 1991-08-16 | 1992-05-19 | Zusammensetzung und verfahren zur behandlung von zystischer fibrose |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0599850B1 (de) |
JP (1) | JPH06510036A (de) |
AT (1) | ATE132742T1 (de) |
AU (1) | AU2143992A (de) |
CA (1) | CA2115364A1 (de) |
DE (1) | DE69207603T2 (de) |
WO (1) | WO1993003709A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004045186B4 (de) * | 2004-05-25 | 2011-08-18 | Engelhard Lyon S.A. | Liposomen, die die intrazelluläre Penetration von Wirkstofen stimulieren, deren Verwendung zur Herstellung von topischen pharmazeutischen bzw. kosmetischen Zusammensetzungen, die diese Liposomen enthalten sowie ein Screening-Verfahren zum Auffinden von Substanzen zur Stimulierung der intrazellulären Penetration |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
EP0702516A4 (de) | 1993-06-01 | 1998-04-22 | Life Technologies Inc | Genetische immunisierung mit kationischen lipiden |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US6075012A (en) * | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US5639661A (en) * | 1994-03-23 | 1997-06-17 | The University Of Iowa Research Foundation | Genes and proteins for treating cystic fibrosis |
US5863563A (en) * | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
US5932241A (en) * | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
US6258792B1 (en) | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
EP0904282B1 (de) | 1996-04-12 | 2001-12-05 | University Of Pittsburgh | Neue kationische cholesterin derivate mit zyklischen polaren gruppen |
US6074667A (en) * | 1996-11-20 | 2000-06-13 | Kinnunen; Paavo | Liposomal transfection method |
US6251425B1 (en) | 1998-10-02 | 2001-06-26 | Igen, Inc. | Glucoside paucilamellar vesicles |
ATE383331T1 (de) | 1998-11-12 | 2008-01-15 | Invitrogen Corp | Transportreagentien |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
WO2005007187A1 (fr) * | 2003-07-14 | 2005-01-27 | Viktor Veniaminovich Tets | Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes |
US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
LT2484375T (lt) | 2006-09-26 | 2018-07-10 | Infectious Disease Research Institute | Vakcinos kompozicija, turinti sintetinio adjuvanto |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
ATE513557T1 (de) | 2006-11-28 | 2011-07-15 | Cls Therapeutics Ltd | Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US7964004B2 (en) | 2007-11-16 | 2011-06-21 | Tk Energi A/S | Feeding apparatus for creation of one or more plugs of compressible material for feeding into a gasifier or reactor |
US9078812B2 (en) | 2007-12-06 | 2015-07-14 | The Bay Zoltan Foundation For Applied Research | Particulate drug carriers as desensitizing agents |
US10251839B2 (en) | 2008-01-22 | 2019-04-09 | Igi Laboratories, Inc. | Lipid vesicles derived from olive oil fatty acids |
US20110052673A1 (en) * | 2008-01-29 | 2011-03-03 | Arthur Tzianabos | Therapeutic compositions |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
WO2009129227A1 (en) | 2008-04-17 | 2009-10-22 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
WO2011017297A2 (en) | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
ES2729967T3 (es) | 2012-02-07 | 2019-11-07 | Infectious Disease Res Inst | Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas |
US20140170159A9 (en) | 2012-03-08 | 2014-06-19 | Ge Wei | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
EP2861245B1 (de) | 2012-06-15 | 2019-10-16 | PDS Biotechnology Corporation | Kationische lipidimpfstoffzusammensetzungen und verfahren zur verwendung |
TWI672149B (zh) | 2012-09-21 | 2019-09-21 | 美商Pds生技公司 | 改良之疫苗組成物及使用方法 |
SG11201503020TA (en) * | 2012-10-29 | 2015-05-28 | Agency Science Tech & Res | A novel reagent for gene-drug therapeutics |
EA201600252A1 (ru) | 2013-09-12 | 2017-05-31 | Галозим, Инк. | Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования |
US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
EP3169310A1 (de) | 2014-07-15 | 2017-05-24 | Life Technologies Corporation | Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen |
EP3200819A4 (de) * | 2014-09-30 | 2018-05-16 | The Medical College of Wisconsin, Inc. | Universalplattform für gezielte therapien zur behandlung von neurologischen erkrankungen |
CN108289932A (zh) | 2015-05-22 | 2018-07-17 | D·D·格恩金 | 胞外dna作为神经变性的治疗靶点 |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
WO2017083820A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
EP4112638A1 (de) | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulierung mit tlr-agonist und verfahren zur verwendung |
EP3463300A1 (de) | 2016-06-01 | 2019-04-10 | Infectious Disease Research Institute | Nanoalum-partikel mit einem leimungsmittel |
JP2019528312A (ja) | 2016-08-07 | 2019-10-10 | ノバルティス アーゲー | mRNA媒介性の免疫化方法 |
CA3041345A1 (en) * | 2016-11-10 | 2018-05-17 | Shrirang KARVE | Improved process of preparing mrna-loaded lipid nanoparticles |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
EP3461487A1 (de) | 2017-09-29 | 2019-04-03 | Nlife Therapeutics S.L. | Zusammensetzungen und verfahren zur abgabe von mrna an leberzellen |
AU2019209770A1 (en) | 2018-01-16 | 2020-09-03 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
AU2019333042A1 (en) | 2018-08-29 | 2021-03-04 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
CN115427021A (zh) | 2020-02-25 | 2022-12-02 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
DK0465529T3 (da) * | 1989-03-21 | 1998-10-05 | Vical Inc | Ekspression af exogene polynukleotidsekvenser i et hvirveldyr |
WO1991002796A1 (en) * | 1989-08-22 | 1991-03-07 | Hsc Research Development Corporation | Cystic fibrosis gene |
-
1992
- 1992-05-19 WO PCT/US1992/004225 patent/WO1993003709A1/en active IP Right Grant
- 1992-05-19 CA CA002115364A patent/CA2115364A1/en not_active Abandoned
- 1992-05-19 AT AT92912632T patent/ATE132742T1/de not_active IP Right Cessation
- 1992-05-19 EP EP92912632A patent/EP0599850B1/de not_active Expired - Lifetime
- 1992-05-19 DE DE69207603T patent/DE69207603T2/de not_active Expired - Fee Related
- 1992-05-19 JP JP5504268A patent/JPH06510036A/ja active Pending
- 1992-05-19 AU AU21439/92A patent/AU2143992A/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004045186B4 (de) * | 2004-05-25 | 2011-08-18 | Engelhard Lyon S.A. | Liposomen, die die intrazelluläre Penetration von Wirkstofen stimulieren, deren Verwendung zur Herstellung von topischen pharmazeutischen bzw. kosmetischen Zusammensetzungen, die diese Liposomen enthalten sowie ein Screening-Verfahren zum Auffinden von Substanzen zur Stimulierung der intrazellulären Penetration |
DE102004045186B9 (de) * | 2004-05-25 | 2012-02-16 | Engelhard Lyon S.A. | Liposomen, die die intrazelluläre Penetration von Wirkstoffen stimulieren, deren Verwendung zur Herstellung von topischen pharmazeutischen bzw. kosmetischen Zusammensetzungen, die diese Liposomen enthalten sowie ein Screening-Verfahren zum Auffinden von Substanzen zur Stimulierung der intrazellulären Penetration |
Also Published As
Publication number | Publication date |
---|---|
EP0599850A1 (de) | 1994-06-08 |
ATE132742T1 (de) | 1996-01-15 |
JPH06510036A (ja) | 1994-11-10 |
DE69207603D1 (de) | 1996-02-22 |
WO1993003709A1 (en) | 1993-03-04 |
AU2143992A (en) | 1993-03-16 |
EP0599850B1 (de) | 1996-01-10 |
CA2115364A1 (en) | 1993-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE132742T1 (de) | Zusammensetzung und verfahren zur behandlung von zystischer fibrose | |
DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
DE69830185D1 (de) | Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen | |
DE69636764D1 (de) | Zusammensetzungen zur behandlung von ischamischem gewebe | |
ATE248586T1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
ATE99949T1 (de) | Natuerliches oberflaechenwirksames lungenpraeparat, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen. | |
ATE132040T1 (de) | Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels | |
DE68924537D1 (de) | Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak. | |
DE69822496D1 (de) | Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen | |
ATA21888A (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken | |
DK0661987T3 (da) | Morphogeninduceret leverregeneration | |
ATE172117T1 (de) | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten | |
DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
DE3787477D1 (de) | Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung. | |
DE69129747D1 (de) | In lösung bringen von proteinen in aktiver form | |
ATE117898T1 (de) | Verfahren und mittel zur präventiven behandlung von chirurgischen adhäsionen. | |
DK325289D0 (da) | Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet | |
ATE5256T1 (de) | Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel. | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
JPH0662428B2 (ja) | 創傷治癒を促進する調製物の製造方法 | |
FR2564831B3 (fr) | Nouveaux derives des acides aroyl- ou hydroaroyl n-alcoyl pyrrolyl-2 carboxyliques et nouvelles compositions pharmaceutiques a action immuno-suppressive | |
RU97107684A (ru) | Способ лечения пузырчатки | |
RU94015015A (ru) | Способ лечения туберкулеза легких |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |